Home Newsfeeds Maxim Group Upgrades NLS Pharmaceutics to Buy, Announces $4 Price Target

Maxim Group Upgrades NLS Pharmaceutics to Buy, Announces $4 Price Target

Maxim Group analyst Jason McCarthy upgrades NLS Pharmaceutics (NASDAQ:NLSP) from Hold to Buy and announces $4 price target.

byBenzinga Newsdesk

December 8, 2022

1 minute read

Maxim Group analyst Jason McCarthy upgrades NLS Pharmaceutics (NASDAQ:NLSP) from Hold to Buy and announces $4 price target.

News
Tech

Tesla Granted U.S. Patent #11537811 Enhanced object detection for autonomous vehicles based on field view

By Charles Gross

December 27, 6:56 AM

https://www.scribd.com/document/616550548/TSLA-Patent

TSLA

Analyst Ratings

What 12 Analyst Ratings Have To Say About Marathon Petroleum

By Benzinga Insights

July 19, 5:04 PM

Over the past 3 months, 12 analysts have published their opinion on Marathon Petroleum (NYSE:MPC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

MPC

Sensus Healthcare, Inc. (SRTS) Soars 8.7%: Is Further Upside Left In The Stock?

By Zacks

July 18, 11:00 AM

Sensus Healthcare, Inc. (NASDAQ: SRTS) shares soared 8.7% in the last trading session to close at $9.89. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 18.5% gain over the past four weeks.

SRTS